Fetus in fetu differs from fetiform teratoma in having an apparent spine and bilateral symmetry.Most authorities agree that fetiform teratomas are highly developed mature teratomas;  the natural history of fetus in fetu is controversial. There also may be a cultural difference, with fetiform teratoma being reported more often in ovarian teratomas (by gynecologists) and fetus in fetu being reported more often in retroperitoneal teratomas (by general surgeons). Fetus in fetu has often been interpreted as a fetus growing within its twin. As such, this interpretation assumes a special complication of twinning, one of several grouped under the term parasitic twin. In this regard, in many cases the fetus in fetu is reported to occupy a fluid-filled cyst within a mature teratoma. Cysts within mature teratoma may have partially developed organ systems; reports include cases of partial cranial bones, long bones and a rudimentary beating heart.Regardless of whether fetus in fetu and fetiform teratoma are one entity or two, they are distinct from and not to be confused with ectopic pregnancy. Struma ovarii
A struma ovarii (also known as goitre of the ovary or ovarian goiter) is a rare form of mature teratoma that contains mostly thyroid tissue. Epignathus
Epignathus is a rare teratoma originating in the oropharyngeal area that occurs in utero. It presents with a mass protruding from the mouth at birth. Untreated, breathing is impossible. An EXIT procedure is the recommended initial treatment. Signs and symptoms
Teratomas may be found in babies, children, and adults.
In December 2021, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for molnupiravir for the treatment of mild-to-moderate coronavirus disease (COVID-19) in adults with positive results of direct SARS-CoV-2 viral testing who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options authorized by the FDA are not accessible or clinically appropriate.In October 2021, the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) started a rolling review of molnupiravir.In November 2021, molnupiravir was approved in the U.K. by the Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of established infections of COVID-19. The MHRA issued a conditional marketing authorization applicable in the U.K., and an emergency use authorization for Northern Ireland.In November 2021, the Bangladesh Directorate General of Drug Administration (DGDA) authorized emergency use of molnupiravir.In January 2022, molnupiravir was approved for medical use in Israel. Names
Molnupiravir is the international nonproprietary name (INN).Generic versions are available under the brand names Molulife (Mankind) and Molena (Emcure). Public health concerns
At a November 2021 AMDAC meeting, multiple advisors raised the concern that molnupiravir could accelerate the emergence of variants of concern. Other scientists raised similar concerns both before and after the meeting. Research
COVID-19 clinical trial
In October 2021, preliminary results from a clinical trial (MOVe-OUT) indicated that treatment with molnupiravir may reduce the risk of hospitalization and death from COVID-19.